← Back to all trials
Not Yet Recruiting
NCT07724535
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
Conditions: Cancer
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: Yes
Phase: PHASE1, PHASE2
Enrollment: 30
Sponsor: Peking University Cancer Hospital & Institute
Location: Peking University Cancer Hospital & Institute Beijing Beijing Municipality
Summary
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Eligibility Criteria
Inclusion Criteria:
1. 18-75 years old;
2. ECOG score 0 or 1 point;
3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
Exclusion Criteria:
1. Pregnant or nursing;
2. Severe hepatic or renal dysfunction;
3. Low WBC (less than 3 x 10\^9/L);
4. Unable to comply with the PET/CT imaging procedures.
Source: ClinicalTrials.gov (NCT07724535). StuddyBuddy aggregates publicly available trial information.
